Review
Efficacy and safety of the PCSK9 inhibitors in the treatment of dyslipidemia in chronic kidney disease
Efectividad y seguridad del uso de inhibidores de PCSK9 en el tratamiento de la dislipemia en el paciente con insuficiencia renal
Borja Quiroga
, Patricia Muñoz Ramos, Vicente Álvarez Chiva
Corresponding author
Servicio de Nefrología, Hospital Universitario de La Princesa, Madrid, Spain
Read
7481
Timeswas read the article
2230
Total PDF
5251
Total HTML
| Year/Month | Html | Total | |
|---|---|---|---|
| 2024 April | 88 | 21 | 109 |
| 2024 March | 88 | 30 | 118 |
| 2024 February | 126 | 59 | 185 |
| 2024 January | 81 | 42 | 123 |
| 2023 December | 75 | 35 | 110 |
| 2023 November | 99 | 39 | 138 |
| 2023 October | 177 | 71 | 248 |
| 2023 September | 189 | 69 | 258 |
| 2023 August | 67 | 28 | 95 |
| 2023 July | 104 | 47 | 151 |
| 2023 June | 82 | 39 | 121 |
| 2023 May | 103 | 71 | 174 |
| 2023 April | 89 | 45 | 134 |
| 2023 March | 112 | 49 | 161 |
| 2023 February | 89 | 40 | 129 |
| 2023 January | 96 | 35 | 131 |
| 2022 December | 119 | 48 | 167 |
| 2022 November | 135 | 67 | 202 |
| 2022 October | 106 | 77 | 183 |
| 2022 September | 108 | 52 | 160 |
| 2022 August | 99 | 47 | 146 |
| 2022 July | 106 | 62 | 168 |
| 2022 June | 104 | 51 | 155 |
| 2022 May | 136 | 45 | 181 |
| 2022 April | 168 | 53 | 221 |
| 2022 March | 159 | 85 | 244 |
| 2022 February | 133 | 73 | 206 |
| 2022 January | 106 | 64 | 170 |
| 2021 December | 86 | 51 | 137 |
| 2021 November | 132 | 52 | 184 |
| 2021 October | 222 | 60 | 282 |
| 2021 September | 390 | 43 | 433 |
| 2021 August | 99 | 54 | 153 |
| 2021 July | 102 | 47 | 149 |
| 2021 June | 115 | 31 | 146 |
| 2021 May | 103 | 68 | 171 |
| 2021 April | 245 | 107 | 352 |
| 2021 March | 248 | 109 | 357 |
| 2021 February | 160 | 71 | 231 |
| 2021 January | 97 | 43 | 140 |
| 2020 December | 97 | 47 | 144 |
| 2020 November | 11 | 3 | 14 |
Show all
